A Study of LY4302814 in Healthy Participants

This study is testing a drug called LY4302814 in healthy volunteers. The main goal is to see how well LY4302814 is tolerated and what side effects it might cause when given either under the skin (SC) or into a vein (IV). Researchers will also take blood samples to understand how your body handles the drug and how the drug affects your body. You may be able to join if you are between 18 and 65 years old, generally healthy, and meet certain weight and body mass index (BMI) requirements. The study will look for serious side effects related to the drug over about 6 months. This study is currently recruiting healthy participants.

Study design: This interventional study plans to enroll 150 healthy participants. It will compare LY4302814 given in two different ways (SC and IV) against a placebo (an inactive substance) also given in two ways.
What's involved: If you participate, the study will last about 6 months and will include at least one overnight stay in a clinical research unit (CRU) for up to 9 days.
Compensation: Not stated in the trial record.
Follow-up: Participants will be monitored for serious adverse events (side effects) from Day 1 through Day 197 after receiving the study drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

A Study of LY4302814 in Healthy Participants

Recruiting

PHASE1Ages 18–65InterventionalBasic science

Eli Lilly and Company

~150 participants

Updated 2026-06-16 on ClinicalTrials.gov

What's tested:LY4302814Placebo

At a glance

Recruiting sites

2 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Measured over Day 1 through Day 197

Conditions

Healthy

Where it's being run

2 sites across 2 states

Florida1

Singapore1

Study leadership

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

[email protected]

1-317-615-4559

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Are overtly healthy as determined by medical evaluation.

Have clinical laboratory test results within the normal range for the population or investigative site or with abnormalities deemed not clinically significant by the investigator.

Have a body weight of 45 kilograms (kg) or greater and body mass index within 18 to 32 kilogram per square meter (kg/m ²), inclusive.

Are individuals assigned female at birth (AFAB) and not of childbearing potential, and individuals assigned male at birth (AMAB). Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Adult participants in Singapore:

Are 21 years of age or older.

Exclusion

Evidence or history of clinically significant conditions.

Have a 12-lead electrocardiogram (ECG) abnormality, that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.

Show evidence of hepatitis B virus (HBV) infection with a positive hepatitis B surface antigen (HBsAg) or anti-hepatitis B core (HBc).

Show evidence of hepatitis C virus (HCV) infection, with positive anti-HCV.

Have human immunodeficiency virus (HIV) infection or positive HIV-1 and HIV-2 antibodies.

Have used or intend to use herbal, vitamin supplements, over-the-counter or prescription medication, within 14 days or 5 half-lives (whichever is longer) prior to dosing and during the study, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.

Smoke more than 5 cigarettes a day, or the equivalent in nicotine-containing products, and/or are unable to abide by clinical research unit (CRU) smoking restrictions.

Have alcohol intake that exceeds recommended average weekly alcohol consumption limits per local regulation, or an amount deemed significant by the investigator.

What this trial measures

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationDay 1 through Day 197

Trialytics